Alzamend Neuro Inc (ALZN)

Name: Alzamend Neuro Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2026-01-31

Latest Quarter

2026-01-31

Revenue

$0.0

Net Income

-$2.2M

Operating Margin

N/A

Free Cash Flow

-$6.9M

Debt / Assets

13.8%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Alzamend Neuro Inc (ALZN).
Income Statement (Quarterly)	2026-01-31	2025-10-31	2025-07-31	2025-01-31
Revenue	0	0	0	0
Cost of Revenue	27,685	27,685	27,685	12,685
Gross Profit	-27,685	-27,685	-27,685	0
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	919,025	821,826	959,334	590,304
Operating Expenses	2,169,969	970,424	2,700,201	1,037,000
Operating Income	-2,197,654	-998,109	-2,700,201	-1,037,000
Interest Expense	1,337	2,649	2,483	2,019
Income Before Tax	-2,198,991	-1,000,758	-2,702,684	-1,039,000
Income Tax Expense	0	0	0	0
Net Income	-2,198,991	-1,000,758	-2,702,684	-1,039,000
Per Share
EPS	-0.58	-0.30	-1.28	-0.19
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Alzamend Neuro Inc (ALZN).
Income Statement (Annual)	2025-04-30	2024-04-30	2023-04-30	2022-04-30	2021-04-30
Revenue	0	0	0	0	0
Cost of Revenue	50,740	0	0	0	0
Gross Profit	-50,740	-50,740	-23,066	0	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	3,031,156	3,483,000	7,425,000	7,118,221	3,641,172
Operating Expenses	4,446,084	9,938,000	14,870,000	12,319,535	4,951,888
Operating Income	-4,496,824	-9,938,000	-14,870,000	-12,319,535	-4,951,888
Interest Expense	18,029	10,101	7,701	46,524	158,803
Income Before Tax	-4,514,853	-9,948,000	-14,878,000	-12,362,059	-5,046,567
Income Tax Expense	0	0	-145,000	42,524	0
Net Income	-4,514,853	-9,948,000	-14,878,000	-12,404,583	-5,046,567
Per Share
EPS	-11.32	-132.33	-2.25	-2.09	-0.06
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Alzamend Neuro Inc (ALZN).
Balance Sheet (Quarterly)	2025-04-30	2024-04-30	2023-04-30	2022-04-30
Assets
Cash and Cash Equivalents	3,948,658	376,048	5,140,859	14,063,811
Short Term Investments	0	0	0	0
Net Receivables	0	0	0	0
Inventory	0	0	0	0
Total Current Assets	4,177,377	455,242	5,835,782	14,413,534
Property Plant Equipment	425,606	176,346	79,843	102,909
Goodwill and Intangibles	0	0	0	0
Total Assets	4,602,983	631,588	5,915,625	14,516,443
Liabilities
Account Payables	634,761	2,925,059	2,870,122	1,162,850
Short Term Debt	0	300,714	0	0
Total Current Liabilities	634,761	3,225,773	2,870,122	1,164,932
Long Term Debt	0	0	0	0
Total Liabilities	634,761	3,225,773	2,870,122	1,164,932
Shareholders Equity
Retained Earnings	-58,535,261	-54,020,408	-44,072,662	-29,194,495
Total Shareholders Equity	3,968,222	-2,594,185	3,045,503	13,351,511

Balance sheet annual history for Alzamend Neuro Inc (ALZN).
Balance Sheet (Annual)	2025-04-30	2024-04-30	2023-04-30	2022-04-30	2021-04-30
Assets
Cash and Cash Equivalents	3,948,658	376,048	5,140,859	14,063,811	1,929,270
Short Term Investments	0	0	0	0	0
Net Receivables	0	0	0	0	16,210
Inventory	0	0	0	0	0
Total Current Assets	4,177,377	455,242	5,835,782	14,413,534	2,912,590
Property Plant Equipment	425,606	176,346	79,843	102,909	0
Goodwill and Intangibles	0	0	0	0	0
Total Assets	4,602,983	631,588	5,915,625	14,516,443	2,912,590
Liabilities
Account Payables	634,761	2,925,059	2,870,122	1,162,850	503,591
Short Term Debt	0	300,714	0	0	335,303
Total Current Liabilities	634,761	3,225,773	2,870,122	1,164,932	899,643
Long Term Debt	0	0	0	0	0
Total Liabilities	634,761	3,225,773	2,870,122	1,164,932	899,643
Shareholders Equity
Retained Earnings	-58,535,261	-54,020,408	-44,072,662	-29,194,495	-16,832,436
Total Shareholders Equity	3,968,222	-2,594,185	3,045,503	13,351,511	2,012,947

Cash flow quarterly history for Alzamend Neuro Inc (ALZN).
Cash Flow Statement (Quarterly)	2025-04-30	2024-04-30	2023-04-30	2022-04-30
Operating Activities
Net Income	-4,514,853	-9,947,746	-14,878,167	-12,362,059
Depreciation & Amortization	50,740	50,740	23,066	3,549
Stock Based Compensation	325,108	955,633	3,582,625	4,408,569
Change in Working Capital	-2,438,467	670,666	2,349,324	1,327,181
Operating Cash Flow	-6,568,186	-8,269,993	-8,923,152	-6,613,990
Investing Activities
Capital Expenditure	-300,000	-147,243	0	-106,458
Investments	-300,000	-147,243	0	-106,458
Investing Cash Flow	-300,000	-147,243	0	-106,458
Financing Activities
Debt Repayment	0	300,000	0	-58,667
Common Stock Issued/Repurchased	2,704,052	1,252,425	989,334	18,911,456
Dividends Paid	0	0	0	0
Financing Cash Flow	10,440,796	3,652,425	200	18,854,989
Summary
Free Cash Flow	-6,868,186	-8,417,236	-8,923,152	-6,720,448
Net Change in Cash	3,572,610	-4,764,811	-8,922,952	12,134,541

Cash flow annual history for Alzamend Neuro Inc (ALZN).
Cash Flow Statement (Annual)	2025-04-30	2024-04-30	2023-04-30	2022-04-30	2021-04-30
Operating Activities
Net Income	-4,514,853	-9,947,746	-14,878,167	-12,362,059	-5,046,567
Depreciation & Amortization	50,740	50,740	23,066	3,549	0
Stock Based Compensation	325,108	955,633	3,582,625	4,408,569	2,032,359
Change in Working Capital	-2,438,467	670,666	2,349,324	1,327,181	-152,451
Operating Cash Flow	-6,568,186	-8,269,993	-8,923,152	-6,613,990	-2,712,027
Investing Activities
Capital Expenditure	-300,000	-147,243	0	-106,458	0
Investments	-300,000	-147,243	0	-106,458	0
Investing Cash Flow	-300,000	-147,243	0	-106,458	100,915
Financing Activities
Debt Repayment	0	300,000	0	-58,667	-1,918
Common Stock Issued/Repurchased	2,704,052	1,252,425	989,334	18,911,456	2,100,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	10,440,796	3,652,425	200	18,854,989	4,450,097
Summary
Free Cash Flow	-6,868,186	-8,417,236	-8,923,152	-6,720,448	-2,712,027
Net Change in Cash	3,572,610	-4,764,811	-8,922,952	12,134,541	1,838,985